As of September 30, 2026, Jiangsu Hengrui Pharmaceuticals Co., Ltd. reported beneficial ownership of 7,420,091 Braveheart Bio, Inc. (BRVE) common shares, or 8.2% of the class. It reported sole voting and sole dispositive power over all those shares, with shared voting and dispositive power each reported as zero. The 8.2% figure is based on 90,038,969 shares of common stock outstanding, as reported in Braveheart Bio’s Form 10-Q filed September 8, 2026.
Braveheart Bio, Inc. (BRVE) and Hengrui Pharma reported 52-week open-label extension results for investigational HRS/BHB-1893 in obstructive hypertrophic cardiomyopathy. All 42 patients resumed treatment after the 12-week core study and washout. At Week 52, peak oxygen uptake rose a mean 2.7 mL/kg/min and KCCQ Clinical Summary Score rose 17.3 points from OLE baseline; 79% (33/42) had a Valsalva LVOT gradient below 30 mmHg.
57% (24/42) ended the study on the 40 mg twice-daily starting dose, and 90% reached the gradient threshold at one or more treatment visits. No on-treatment severe or serious adverse events were reported; two patients had transient site-measured LVEF reductions below 50% and resumed at a lower dose. A separate post hoc analysis of 84 non-obstructive HCM patients reported improvements across diastolic-function indices after 12 weeks. A fixed-dose Phase 2b oHCM study, TRUEHEART-HCM, was planned.
Braveheart Bio, Inc. common stock is the subject of ownership reports by FMR LLC and Abigail P. Johnson, each reporting beneficial ownership of 7,374,365 shares, or 8.2% of the class. FMR LLC reports sole voting and dispositive power over 7,374,365 shares; Abigail P. Johnson reports sole dispositive power over that same amount and zero voting power. Both report zero shared voting and dispositive power.
Braveheart Bio, Inc. (BRVE) received an amended Schedule 13D from OrbiMed-related entities reporting their current beneficial ownership of the company’s common stock. OrbiMed Advisors LLC, OrbiMed Capital GP IX LLC and OrbiMed Genesis GP LLC together report beneficial ownership of 12,175,159 shares, representing 13.5% of Braveheart Bio’s outstanding common stock.
The amendment states that the Reporting Persons’ percentage ownership decreased by more than 1% as a result of an increase in the number of Braveheart Bio shares outstanding, rather than from share sales. OrbiMed Private Investments IX, LP holds 11,901,826 shares (13.2%), and OrbiMed Genesis Master Fund, L.P. holds 273,333 shares (0.3%), with OrbiMed entities sharing voting and dispositive power over these positions. The filing also describes existing investors’ rights and lock-up agreements tied to Braveheart Bio’s IPO.
Braveheart Bio, Inc. (BRVE) reported its first full half-year as a clinical-stage public-ready company, focused on lead cardiac myosin inhibitor BHB-1893 for hypertrophic cardiomyopathy. For the six months ended June 30, 2026, it generated no revenue and recorded a net loss of $29.3 million, driven by $22.0 million in research and development and $8.9 million in general and administrative expenses as Phase 3 preparation ramped up.
As of June 30, 2026, Braveheart held $122.8 million in cash and cash equivalents and total assets of $127.0 million, with liabilities of $9.3 million; operations have been funded primarily through redeemable convertible preferred stock. A subsequent August 7, 2026 IPO raised approximately $404.5 million in net proceeds at $18.00 per share, and management states that existing cash plus IPO proceeds should fund projected operating and capital needs into 2029 as it advances BHB-1893 through global Phase 3 trials in obstructive and non-obstructive HCM.
Braveheart Bio, Inc. (BRVE) reported unaudited results for the quarter ended June 30, 2026 and outlined progress on its lead cardiac myosin inhibitor BHB-1893. The company ended the quarter with $122.8 million in cash and cash equivalents, which, together with $404.5 million in net IPO proceeds received in August, would have brought cash to about $527.3 million on an as-adjusted basis. Management estimates this cash runway will fund operations into 2029.
R&D expenses rose to $11.1 million from virtually zero a year earlier, and G&A expenses increased to $4.8 million, leading to a quarterly net loss of $15.0 million and net loss attributable to common stockholders of $18.6 million, or $2.51 per share. The company has initiated the global Phase 3 LIONHEART-HCM trial in obstructive HCM and plans to start the NOBLEHEART-HCM Phase 3 trial in non-obstructive HCM in the first half of 2027, following encouraging Phase 2 data in both settings.
Braveheart Bio, Inc. (BRVE) is the subject of a Schedule 13D reporting a significant ownership position by investment entities affiliated with OrbiMed. OrbiMed Advisors LLC, together with OrbiMed Capital GP IX LLC and OrbiMed Genesis GP LLC, reports beneficial ownership of 12,175,159 Braveheart common shares, representing 17.2% of the 70,652,838 shares outstanding as referenced in a Form S-1 amendment.
The stake is largely held through OrbiMed Private Investments IX, LP (11,901,826 shares, about 16.9%), with an additional 273,333 shares held by OrbiMed Genesis Master Fund, L.P. These positions arose from purchases of common and Series A preferred stock in 2025 and from buying Braveheart shares in the IPO at $18.00 per share, with all preferred and pre-IPO common converting into common at a 1-for-4.38 ratio upon the IPO. OrbiMed describes the holdings as investment positions, not intended to acquire control on behalf of advisory clients, but it retains flexibility to buy or sell shares over time.
OrbiMed-affiliated funds have registration rights under an Investors' Rights Agreement, including demand, piggyback, and Form S-3 rights (for offerings with anticipated net proceeds of at least $5 million), subject to timing and frequency limits and expiring no later than the third anniversary of the IPO. OPI IX and director Erez Chimovits are also subject to a 180-day IPO lock-up restricting sales and hedging transactions. OrbiMed Advisors, as managing member of the general partners for the OrbiMed funds, shares voting and dispositive power and may be able to influence Braveheart through Chimovits' board seat.
Braveheart Bio, Inc. director Vineeta Agarwala reported initial ownership on a Form 3. The filing shows 10,232,420 shares of Common Stock held indirectly through AH Bio Fund IV, L.P., which also acts as nominee for several affiliated funds. AH Equity Partners Bio IV, L.L.C. is the general partner of AH Bio Fund IV and has sole voting and dispositive power over these securities. Agarwala is a member of AH Equity Partners Bio IV but disclaims beneficial ownership of the securities held by AH Bio Fund IV, except to the extent of any pecuniary interest.
Braveheart Bio, Inc. has a new large shareholder disclosure from Andreessen Horowitz–affiliated funds and principals. AH Bio Fund IV, L.P. and related entities beneficially own 10,232,420 shares of common stock, representing 11.4% of outstanding shares immediately after the IPO. The stake arose from the conversion of 40,000,000 Series A preferred shares purchased for $40 million, which converted at a 4.38‑for‑1 ratio into 9,132,420 common shares at IPO closing on August 7, 2026, plus an additional 1,100,000 common shares bought in the IPO at $18.00 per share for $19.8 million.
AH Equity Partners Bio IV, L.L.C. is the general partner and holds sole voting and dispositive power over the fund’s shares, while Marc Andreessen and Benjamin Horowitz may be deemed to share voting and dispositive power through their roles as managing members. The investors acquired the position for investment purposes and may increase or decrease their holdings, subject to a 180‑day lock‑up and an Investors’ Rights Agreement that provides demand, shelf (Form S‑3), and piggyback registration rights for sizable future resales.
Frazier Life Sciences investment entities report beneficial ownership in Braveheart Bio, Inc. common stock. Frazier Life Sciences Public Fund, L.P. directly holds 4,976,457 shares, representing 5.5% of the common stock based on 90,038,969 shares anticipated to be outstanding after the company’s initial public offering described in an August 6, 2026 prospectus. Related Frazier Life Sciences funds collectively hold smaller positions of 20,361 and 110,554 shares through separate Delaware limited partnerships and LLCs, each with shared voting and dispositive power and no sole voting or dispositive power reported.